All News
Filter News
Found 808,690 articles
-
Data from the MIV-711 Phase II Program to be Presented at the OARSI World Congress
4/30/2019
Medivir AB informs that new data from the phase II program of MIV-711, will be presented during the Osteoarthritis Research Society International world congress, which will take place 2-5 May in Toronto, Canada.
-
Invitation to the presentation of Recipharm’s interim report January - March 2019
4/30/2019
Recipharm AB will publish its interim report for January-March 2019 on 3 May at 07:45 am CET.
-
Levita Magnetics Announces Expanded Indication of Magnetic Surgical System for Use in Prostatectomy Procedures
4/30/2019
Technology Minimizes Invasiveness of Certain Laparoscopic and Robotic Surgeries, Enabling Procedures with a Reduced Number of Incisions While Facilitating Surgical Access and Visualization
-
Vividion Therapeutics Announces Oversubscribed $82 Million Series B Financing
4/30/2019
Bolsters capital to advance lead programs into the clinic and broaden early-stage pipeline of therapeutics against previously intractable drug targets
-
Synlogic Presents Data Describing a Solid Oral Formulation Process for Synthetic Biotic™ Medicine SYNB1618 for the Treatment of PKU at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
4/30/2019
Synlogic’s robust and reproducible lyophilization process provides a solid formulation of SYNB1618 with improved quality attributes, stability and minimal loss of viability compared to liquid formulation
-
Blue Cross Blue Shield Association and Blue Health Intelligence Invite Cutting-Edge Companies to Enter the BlueCross BlueShield Data Innovation Challenge
4/30/2019
The Blue Cross Blue Shield Association and Blue Health Intelligence® invite visionary companies to enter the BlueCross BlueShield Data Innovation Challenge to develop solutions that increase access to care, enhance patient engagement, and improve care delivery and outcomes.
-
RLDatix Names Jeff Surges as CEO
4/30/2019
RLDatix, a leading provider of solutions that drive patient safety, quality improvement and harm reduction in healthcare, announced today that Jeff Surges has been appointed as CEO, effective immediately.
-
Kinetic River Corp. Receives Phase II SBIR Grant From the National Institutes of Health
4/30/2019
2-Year Grant Supports Continued Development of a Compensation-Free Flow Cytometer
-
Biom'up reports 2018 full-year results and confirms strong commercial uptake in 1st quarter of 2019
4/30/2019
Biom'up announced its full-year results for the year ending December 31, 2018, as approved by the Company's Board of Directors on April 29, 2019, and provided an update on its operations.
-
EyeSouth Expands into Tennessee Through Affiliation with Two Practices and Associated ASCs in Cookeville and Crossville
4/30/2019
EyeSouth Partners is pleased to announce that it has completed an affiliation with Cumberland Eye Care and Plateau ASC, located in Crossville, TN, and Cookeville Eye Specialists and Perimeter ASC, located in Cookeville, TN.
-
China Biologic Products to Report First Quarter 2019 Financial Results
4/30/2019
China Biologic Products Holdings, Inc. announced that the Company plans to release its first quarter 2019 financial results on Friday, May 10, 2019 after the market closes.
-
Incyte Reports 2019 First Quarter Financial Results and Provides Updates on Key Clinical Programs
4/30/2019
Total revenues of $498 million (+30% vs Q1 2018) and total product-related revenues of $458 million (+20% vs Q1 2018) for the quarter ended March 31, 2019
-
Dynacure Announces Approval of Clinical Trial Application for DYN101, an Antisense Medicine to Treat Rare Disease 'Centronuclear Myopathies'
4/30/2019
Company expects to initiate Phase 1 / 2 study 'Unite-CNM' in 2H2019
-
In2Bones Announces the Global Launch of the TriWay® TibioTaloCalcaneal (TTC) Nail Arthrodesis System
4/30/2019
In2Bones Global, Inc. announced the global launch of the TriWay® TibioTaloCalcaneal Nail Arthrodesis System.
-
Audentes Therapeutics to Release First Quarter 2019 Financial Results and Provide Corporate Update on Tuesday, May 7, 2019
4/30/2019
Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, will host a conference call and webcast to report its first quarter 2019 financial results and provide a corporate update on Tuesday, May 7, 2019.
-
US Specialty Care Named Finalist for 2019 Patient Choice Awards; Third Year in a Row
4/30/2019
US Specialty Care, WellDyneRx's wholly-owned specialty pharmacy, was named a finalist in the Annual Patient Choice Awards for a third year in a row.
-
Caprion Biosciences expands its global biomarker and immune monitoring franchise by acquiring Serametrix Corporation
4/30/2019
Caprion Biosciences announced that the company acquired Serametrix Corporation, a specialized provider of immune monitoring services headquartered in Carlsbad, California.
-
GENFIT: Reports First quarter 2019 Financial Information
4/30/2019
Following the capital increase and listing on Nasdaq, cash and cash equivalents totaled €314.1 million as of March 31, 2019
-
South Africa Hospital Delivers HDR Brachytherapy Cancer Treatments with Varian Bravos Afterloader System
4/30/2019
Varian announced Groote Schuur Hospital in Cape Town, South Africa is the first hospital in Africa to deliver High Dose Rate brachytherapy treatments with the Bravos™ afterloader system.
-
LabCorp Announces 2019 First Quarter Results and Increases 2019 Earnings Guidance
4/30/2019
Q1 revenue of $2.79 billion, down 2% from $2.85 billion last year